Reference health
A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders
1 of 40 checkable references need attention · checked 2026-07-22
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
does not resolve to a known work10.1002/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D
The 39 checked references that resolve
resolves10.1212/WNL.0000000000000363
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders [RETIRED]
resolves10.1089/can.2015.0012
Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy
resolves10.1111/j.1365-2125.2012.04164.x
Novel Δ<sup>9</sup>‐tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects
resolves10.1007/s00213-015-3889-y
Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia
resolves10.3389/fphar.2016.00422
Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
resolves10.1016/j.schres.2015.01.033
A systematic review of the antipsychotic properties of cannabidiol in humans
resolves10.1136/bmj.d5928
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
resolves10.1097/00004714-198306000-00004
A Double-Blind Trial of ??9-Tetrahydrocannabinol in Primary Anorexia Nervosa
resolves10.1002/eat.22173
Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial
resolves10.1002/j.1552-4604.1981.tb02617.x
The Efficacy and Safety of Nabilone (A Synthetic Cannabinoid) in the Treatment of Anxiety
resolves10.1007/BF00432554
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
resolves10.1038/npp.2011.6
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients
resolves10.1177/0269881110379283
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
resolves10.1016/j.psyneuen.2014.11.002
The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study
resolves10.1038/tp.2012.15
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
resolves10.1097/JCP.0b013e31820e861c
Randomized, Controlled Crossover Trial of Dronabinol, 2.5 mg, for Agitation in 2 Patients With Dementia
resolves10.1016/j.jagp.2015.07.011
Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial
resolves10.1136/jnnp.2009.200642
Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial
resolves10.1002/mds.1280
Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia
resolves10.1016/j.baga.2011.04.002
Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial
resolves10.1016/0091-3057(91)90386-G
Controlled clinical trial of cannabidiol in Huntington's disease
resolves10.1002/mds.22809
A pilot study using nabilone for symptomatic treatment in Huntington's disease
resolves10.1007/s00415-016-8145-9
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease
resolves10.1212/WNL.57.11.2108
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
resolves10.1177/0269881114550355
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
resolves10.1055/s-2002-25028
Treatment of Tourette's Syndrome with Δ<sup>9</sup>-Tetrahydrocannabinol (THC): A Randomized Crossover Trial
resolves10.4088/JCP.v64n0417
Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome
resolves10.1371/journal.pmed.1000097
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
resolves10.1038/npp.2009.184
Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
The 1 reference without a DOI — listed, not checked
no DOI — not checkedZuardi, AW, Morais, SL, Guimarães, FS, and Mechoulam, R (1995). Antipsychotic effect of cannabidiol. J Clin Psychiatry. 56, 485-486.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.9758/cpn.2017.15.4.301"><img src="https://citestamp.com/citestamped/10.9758/cpn.2017.15.4.301/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.9758/cpn.2017.15.4.301)